Malyutina Sofia, Mazurenko Elena, Mazdorova Ekaterina, Shapkina Marina, Avdeeva Ekaterina, Mustafina Svetlana, Simonova Galina, Ryabikov Andrey
Research Institute of Internal and Preventive Medicine-Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, 630089 Novosibirsk, Russia.
J Pers Med. 2022 Oct 10;12(10):1689. doi: 10.3390/jpm12101689.
We aimed to analyze the profile of glucose lowering therapy (GLT) in persons with diabetes mellitus type 2 (DM2) in an aging Russian population. A random population sample (n = 3898, men/women, 55−84) was examined in Novosibirsk, during 2015−2018 (HAPIEE Project). The design of the present work is a cross-sectional study. DM2 was defined in those with a history of DM2 receiving GLT, or at a level of fasting plasma glucose (FPG) ≥7.0 mmol/L. The entire DM2 group was included in the analysis (n = 803); of these, 476 persons were taking GLT and were included in the analysis at stage 2. Regular GLT medication intake for 12 months was coded with ATC. In studied sample, the prevalence of DM2 was 20.8%. Among subjects with DM2, 59% of individuals received GLT, 32% did not. Glycemic control (FPG < 7.0 mmol/L) was achieved in every fifth participant with DM2 (35% in those receiving GLT). In frequency of GLT use, biguanides ranked in first place (75%), sulfonylurea derivatives in second (35%), insulins in third (12%), and iDPP-4 in fourth (5%). Among those receiving GLT, 24% used combined oral therapy, and 6% used insulin-combined therapy. In conclusion, in a population sample aged 55−84 examined in 2015−2018, glycemic control was achieved in every fifth participant with DM2, and in every third participant receiving GLT. The proportion of participants using new GLT drugs was small, and there was a lack of HbA1c monitoring for intensive glycemic control.
我们旨在分析俄罗斯老龄人群中2型糖尿病（DM2）患者的降糖治疗（GLT）情况。2015年至2018年期间（HAPIEE项目），在新西伯利亚对一个随机抽取的人群样本（n = 3898，年龄55 - 84岁，男女皆有）进行了检查。本研究采用横断面研究设计。DM2定义为有接受GLT治疗的DM2病史者，或空腹血糖（FPG）水平≥7.0 mmol/L者。整个DM2组纳入分析（n = 803）；其中，476人正在接受GLT治疗，并在第二阶段纳入分析。使用解剖学治疗学及化学分类系统（ATC）对连续12个月规律服用GLT药物进行编码。在研究样本中，DM2的患病率为20.8%。在DM2患者中，59%的个体接受GLT治疗，32%未接受。每五名DM2患者中有一名实现了血糖控制（FPG < 7.0 mmol/L，接受GLT治疗者中为35%）。在GLT使用频率方面，双胍类药物位居首位（75%），磺脲类衍生物位居第二（35%），胰岛素位居第三（12%），二肽基肽酶-4抑制剂（iDPP-4）位居第四（5%）。在接受GLT治疗者中，24%使用联合口服治疗，6%使用胰岛素联合治疗。总之，在2015年至2018年检查的55 - 84岁人群样本中，每五名DM2患者中有一名实现了血糖控制，每三名接受GLT治疗的患者中有一名实现了血糖控制。使用新型GLT药物的参与者比例较小，且缺乏用于强化血糖控制的糖化血红蛋白（HbA1c）监测。
